Turning Point Benefit Group, Inc. Viking Therapeutics, Inc. Transaction History
Turning Point Benefit Group, Inc.
- $191 Billion
- Q4 2025
A detailed history of Turning Point Benefit Group, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Turning Point Benefit Group, Inc. holds 18 shares of VKTX stock, worth $716. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18Holding current value
$716% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
442Shares Held
66MCall Options Held
7.18MPut Options Held
3.87M-
Vanguard Group Inc Valley Forge, PA9.98MShares$397 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$240 Million0.01% of portfolio
-
State Street Corp Boston, MA4.51MShares$180 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.73MShares$148 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.58MShares$103 Million0.0% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.05B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...